PAVmed Inc. (PAVM) 股票分析

公司概述

PAVmed Inc. is a medical device company dedicated to acquiring, developing, and commercializing novel products designed to address unmet clinical needs within the United States healthcare market. The firm operates specifically within the healthcare sector, focusing on the medical devices industry where innovation in surgical tools and minimally invasive technologies is critical for patient care outcomes. At its current scale, the company maintains a market capitalization of $62.14M while employing a workforce of 41 individuals and generating total revenue of $71,000 over the trailing twelve months. These financial figures indicate that PAVmed is a small-cap entity with very limited revenue generation relative to its market valuation, suggesting the company is likely in an early-stage development or commercialization phase where significant capital investment precedes substantial income realization.

财务健康

The company reports trailing twelve-month revenue of $71,000 against a net income of -$3,774,000, while EBITDA stands at -$21,701,000. The substantial negative gap between the nominal revenue of $71,000 and the net loss of $3.774 million reveals a highly aggressive cost structure where operating expenses significantly outweigh current sales, a typical characteristic of biotech firms burning cash to fund research and product launch. Free cash flow is reported at -$13,997,875, indicating a heavy reliance on external capital sources such as equity issuance or debt financing to sustain operations rather than generating internal liquidity. The gross margin is -207.0%, the operating margin is -13082.7%, and the profit margin is 564.8%; these anomalous figures, particularly the negative gross margin, suggest that cost of goods sold calculations may include significant upfront capitalization or inventory write-downs common in pre-revenue device development, while the profit margin exceeding 100% mathematically reflects losses that are smaller in magnitude than the negative revenue base. On the liability side, the company holds $1.95M in cash against $13.35M in debt, resulting in a debt-to-equity ratio of 59.86, which indicates a highly leveraged balance sheet with limited equity cushion to absorb further losses. The current ratio of 0.17 further underscores severe short-term liquidity constraints, as current assets are less than one-third of current liabilities, implying potential difficulty in meeting immediate obligations without refinancing or new capital. Return on equity stands at -32.3% and return on assets at -39.2%, metrics that reveal management has not yet achieved profitability and that the capital deployed to date has resulted in value destruction rather than value creation under current accounting periods.

估值评估

Valuation metrics for PAVmed present a complex picture due to its lack of earnings, with the P/E ratio (TTM) listed as N/A and a forward P/E of -0.58. The existence of a negative forward P/E implies that the market is pricing in expected losses in the near term or that traditional earnings-based valuation multiples are inapplicable for this stage of the company. The price-to-book ratio is 0.98, indicating that the market values the company at nearly its book value, which offers a baseline comparison for asset-heavy or tangible-device firms even when earnings are negative. Alternative valuation multiples such as the price-to-sales ratio of 875.25 and an EV/EBITDA of -3.99 suggest that the market is paying an extremely high premium for every dollar of sales, reflecting high expectations for future product adoption or significant dilution risk associated with the company's current valuation. Regarding price action, the stock has a 52-week high of $28.44 and a 52-week low of $6.00; without the specific current share price provided in the facts, the position relative to this range cannot be calculated, but the wide range highlights significant price volatility experienced over the last year. The beta value is 0.81, which indicates that the stock's price volatility is slightly lower than the broader market average, suggesting that while the stock can move independently, it does not exhibit the extreme leverage-like swings often seen in speculative biotech small-caps.

Growth & Income

The company demonstrates a revenue growth rate of 420.0% year-over-year, while earnings growth is listed as N/A due to the absence of profitable earnings in the prior period. The absence of positive earnings growth metrics means that revenue expansion is not yet translating into bottom-line profitability, a common trajectory for companies still ramping up commercialization efforts for their lead products like CarpX. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flow is being retained and reinvested into the business to fund further product development and market expansion rather than being distributed to shareholders. This reinvestment strategy is essential for a firm with high negative margins and significant debt, as it prioritizes long-term product pipeline growth over immediate shareholder returns. Overall, the growth and income profile of PAVmed is characterized by explosive top-line revenue growth coupled with deep structural losses and a complete reliance on capital markets for funding operations.